Comparative Analysis of Pediatric and Adult Mastocytosis: Clinical Presentation, Triggers, and Treatment Patterns from a Tertiary Care Registry
Authors:
- Sundus M. NoorSaeedSNSundus M. NoorSaeed
- Roy KhalafRKRoy Khalaf
- Athari AleneziAAAthari Alenezi
- Eviatar FieldsEFEviatar Fields
- Connor ProstyCPConnor Prosty
- Abdulaziz S. AlrafiaahAAAbdulaziz S. Alrafiaah
- Barbara MiedzybrodzkiBMBarbara Miedzybrodzki
- Elena NetchiporoukENElena Netchiporouk
- John SampalisJSJohn Sampalis
- Michael FeinMFMichael Fein
- Moshe Ben-ShoshanMBMoshe Ben-Shoshan
Open Access
Abstract
Background: Mastocytosis is a rare hematologic disorder, classified into cutaneous mastocytosis (CM) and systemic mastocytosis (SM). Understanding age-related differences in presentation and management is essential for individualized care. Methods: Data from patients recruited from the Montreal Children’s and Montreal General Hospitals between 2015 and 2024 were analyzed. Descriptive statistics were employed to present patient demographics, clinical characteristics, and medication usage. Statistical analyses included Fisher’s exact test for categorical variables and t-tests or non-parametric equivalents for continuous variables. Results: A total of 63 patients were included, comprising 39 children and 24 adults. Children had a median age of 1.9 years, while adults had a median age of 49.3 years. CM was exclusively prevalent in children (100.0%), while SM was more common in adults (45.8%). Adults with SM had a significantly higher median age than CM (49.4 versus 44.7 years, respectively, p = 0.03). Epinephrine use was more frequent in adult SM patients (36.4% versus 0%, respectively, p = 0.03). No pediatric patients required epinephrine for symptom control. Conclusions: This study highlights important clinical differences between pediatric and adult mastocytosis. CM was more common in children while SM predominated in adults and was associated with greater flare severity and higher tryptase levels.Keywords
This publication has 19 references indexed in Scilit:
- Prevalence and incidence of mastocytosis in adults: a Danish nationwide register studyEuropean Journal of Epidemiology, 2025
- Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNMThe Journal of Allergy and Clinical Immunology: In Practice, 2024
- Safety of COVID-19 mRNA vaccination and effects of SARS-CoV-2 infection in children and adults with mast cell disordersClinical and Experimental Medicine, 2023
- Evidence-based use of antihistamines for treatment of allergic conditionsAnnals of Allergy, Asthma & Immunology, 2023
- Prevalence of mastocytosis and Hymenoptera venom allergy in the United StatesJournal of Allergy and Clinical Immunology, 2021
- Criteria for the Regression of Pediatric Mastocytosis: A Long-Term Follow-UpThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the FutureCancer Research, 2017
- KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on MastocytosisLeukemia, 2015
- Risk factors and management of severe life‐threatening anaphylaxis in patients with clonal mast cell disordersClinical & Experimental Allergy, 2014
- The role of mast cells in allergic inflammationRespiratory Medicine, 2012